Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mixed Data For Bluebird's LentiGlobin, But Conditional Approval On The Cards

Executive Summary

Over the last week bluebird bio has reported first interim Phase III data from the Northstar-2 trial of blood disease drug LentiGlobin and announced a public offering of $350m of common stock.

You may also be interested in...



Bluebird Bio Sings Cheerily Of Its "Biggest ASH Ever"

Company highlights LentiGlobin sickle cell and beta thalassemia data updates in investor call about the upcoming ASH meeting, which will feature 11 presentations across its clinical and preclinical programs.

Cell And Gene Therapies: Where Few Standard Rules Apply

Manufacturing, distribution and pricing challenges for cell and gene therapies have been mostly hypothetical – until now. But with no industry standards, the first products to win approval are dictating the complex path forward.

Deal Watch: CSL Behring's Calimmune Buy Builds On Its Base & Adds Platform Tech

Acquisition of gene therapy company Calimmune expands on CSL Behring's hematology franchise and fits rare disease business model, plus adds platform tech with wide application for CSL's portfolio.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel